Background and Objective: Our goal is to obtain insight into the causes of the pathological lesions in Alzheimer’s disease (AD). It is thought that the β-amyloid (Aβ) deposits within the cerebral cortex and hippocampus of AD brains are initiated by a ‘bad seed’ of oligomeric Aβ. The origin of this seed is unknown. Here, we focused on the events that might trigger the formation of neuritic plaques, aiming to explain how these plaques form in cortical and hippocampal regions. Methods and Results: Using immunocytochemical and biochemical methods, we showed that brainstem-derived, neuronal cells (CAD) – but not cortical or hippocampal neurons – show large amounts of Aβ accumulated at the terminals of their processes. This is similar to what is believed to occur in brain neurons, in the early phases of AD. CAD cells that contain Aβ accumulations also concentrate β-secretase at process terminals. We show that, while the anterograde transport of small vesicles is not significantly affected, the mitochondrial transport is perturbed in CAD cells that contain Aβ accumulations. We further show that intracellular, neuritic Aβ accumulations may become extracellular upon neurite degeneration, thus providing the initial ‘bad seed’ of Aβ oligomers that triggers further aggregation of extracellular proteins. Conclusion: We propose that brainstem neurons, known to send projections throughout the brain, could provide the ‘bad seed’ of Aβ that nucleates plaques in the cerebral cortex and hippocampus of AD brains.
© 2008 S. Karger AG, Basel
- Alzheimer’s disease
- β-Amyloid precursor protein
- β-Amyloid peptide
- Neuritic plaques
- Brainstem neurons
- CAD cells
- Selkoe DJ: Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 2001;81:741–766.
- Harper JD, Lansbury PT Jr: Models of amyloid seeding in Alzheimer’s disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 1997;66:385–407.
- Qi Y, Wang JK, McMillian M, Chikaraishi DM: Characterization of a CNS cell line, CAD, in which morphological differentiation is initiated by serum deprivation. J Neurosci 1997;17:1217–1225.
- Muresan Z, Muresan V: A phosphorylated, carboxy-terminal fragment of β-amyloid precursor protein localizes to the splicing factor compartment. Hum Mol Genet 2004;13:475–488.
- Muresan Z, Muresan V: c-Jun NH2-terminal kinase-interacting protein-3 facilitates phosphorylation and controls localization of amyloid-beta precursor protein. J Neurosci 2005;25:3741–3751.
- Muresan Z, Muresan V: Coordinated transport of phosphorylated amyloid-beta precursor protein and c-Jun NH2-terminal kinase-interacting protein-1. J Cell Biol 2005;171:615–625.
- Muresan Z, Muresan V: Neuritic deposits of amyloid-β peptide in a Subpopulation of central nervous system-derived neuronal cells. Mol Cell Biol 2006;26:4982–4997.
- Muresan Z, Muresan V: The amyloid-β precursor protein is phosphorylated via distinct pathways during differentiation, mitosis, stress, and degeneration. Mol Biol Cell 2007;18:3835–3844.
- Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG: Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003;300:486–489.
- Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, Gouras GK: Oligomerization of Alzheimer’s beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci 2004;24:3592–3599.
- Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, Mohan PS, Mercken M, Farmery MR, Tjernberg LO, Jiang Y, Duff K, Uchiyama Y, Naslund J, Mathews PM, Cataldo AM, Nixon RA: Macroautophagy – A novel beta-amyloid peptide-generating pathway activated in Alzheimer’s disease. J Cell Biol 2005;171:87–98.
- Aston-Jones G, Cohen JD: An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci 2005;28:403–450.
- German DC, Nelson O, Liang F, Liang CL, Games D: The PDAPP mouse model of Alzheimer’s disease: locus coeruleus neuronal shrinkage. J Comp Neurol 2005;492:469–476.
- Hertz L: Is Alzheimer’s disease an anterograde degeneration, originating in the brainstem, and disrupting metabolic and functional interactions between neurons and glial cells? Brain Res Brain Res Rev 1989;14:335–353.
- Mann DM, Yates PO, Hawkes J: The pathology of the human locus ceruleus. Clin Neuropathol 1983;2:1–7.
- Saper CB, Wainer BH, German DC: Axonal and transneuronal transport in the transmission of neurological disease: potential role in system degenerations, including Alzheimer’s disease. Neuroscience 1987;23:389–398.
Department of Pharmacology and Physiology, University of Medicine and Dentistry of New Jersey – New Jersey Medical School, 185 South Orange Avenue, MSB, I-665
Newark, NJ 07103 (USA)
Tel. +1 973 972 4385, Fax +1 973 972 7950, E-Mail email@example.com
Published online: March 6, 2008
Number of Print Pages : 4
Number of Figures : 4, Number of Tables : 0, Number of References : 16
Vol. 5, No. 3-4, Year 2008 (Cover Date: March 2008)
Journal Editor: Nitsch R.M. (Zürich), Hock C. (Zürich)
ISSN: 1660–2854 (Print), eISSN: 1660–2862 (Online)
For additional information: http://www.karger.com/NDD
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.